Table of contents
- Original news
- What is the background to this judgment?
- What evidence did the court take into account?
- How did the court approach applying the law on quia timet injunctions?
- What kind of intention is necessary?
- How should the injunction request be dealt with in a statement of case?
- What is the correct date for assessing the threat level?
- How does this decision affect generics companies’ activities close to patent expiry?
Article summary
IP & IT analysis: How might the recent decision in Merck Sharp Dohme Corp v Teva Pharma BV affect generics companies’ activities close to patent expiry?
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial